Targeted Therapy

Differentiation therapy holds promise as a targeted therapy for pediatric neuroblastoma

By

The important role of microRNAs in regulating neuroblastoma development has been unveiled by new research.

Targeted drug may prolong survival for patients with cervical cancer

By

A new clinical study has found that erlotinib has promising potential to improve treatment for cervical cancer.

Novel biologic drug holds promise for individualized ovarian cancer treatment

By

Researchers have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy.

Fast and effective mechanism combats ovarian tumors

By

A new type of strategy has been proposed to tackle an aggressive subtype of ovarian cancer by using a nanoscale drug-delivery system designed to target specific cancer cells.

New target found for triple-negative breast cancer

By

A new study shows that targeting a particular nuclear protein may provide an effective approach for treating triple-negative breast cancer.

Potential options to attack stem cells in triple-negative breast cancer

By

A protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells, according to new research.

TCGA study of bladder cancer reveals potential drug targets

TCGA study of bladder cancer reveals potential drug targets

By

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer.

New hormone receptor targets for breast cancer discovered

New hormone receptor targets for breast cancer discovered

By

Androgen and vitamin D receptors can be targeted in breast cancer, according to new research.

Targeted therapy succeeds for common form of lung cancer in initial testing

Targeted therapy succeeds for common form of lung cancer in initial testing

By

The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two drugs already in use in laboratory and animal studies.

Complete recovery from hairy cell leukemia after vemurafenib treatment

By

Vemurafenib, a BRAF inhibitor that has been approved as a treatment for advanced melanomas, has also proved successful in treating hairy cell leukemia.

Cellular senescence leads to acute promyelocytic leukemia cure

By

Targeted treatments for acute promyelocytic leukemia cause a cascade of molecular events that lead to cellular senescence and recovery. This action model could be activated in other types of cancers.

Subtypes of HER2-positive breast cancer with varying sensitivities identified

By

Research has not only shown that HER2-positive breast cancer can be classified into four different subtypes, but has also unmasked a subtype showing both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy.

Targetable mutation identified in rare brain tumor

By

A gene mutation associated with several types of cancer also may be responsible for a rare but debilitating brain tumor called papillary craniopharyngioma.

Multiple myeloma study uncovers genetic diversity within tumors

By

The most comprehensive genetic study to date of the blood cancer multiple myeloma has revealed that the genetic landscape of the disease may be more complicated than previously thought.

Piggy-backing proteins ride white blood cells to destroy metastasizing cancer

By

A new technique targets metastasizing cancer cells that are traveling through the bloodstream by hitching cancer-killing proteins on white blood cells.

Molecular and protein-targeting therapies best for lung cancer with KRAS mutation

By

Therapies specifically targeting the molecular profile of non-small cell lung cancer (NSCLC) with mutated KRAS, a cancer-causing protein, are the most effective treatment strategies for patients with NSCLC.

Target of potent drug for chronic leukemia is confirmed

By

A new study helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.

Known lung oncogenes ALK and ROS1 also drive colorectal cancer

By

ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers, which implies that drugs that target ALK and ROS1 in lung cancer may also have applications for colorectal cancer.

Potential therapeutic target identified for incurable, rare type of soft-tissue cancer

By

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, according to a new research report.

Targeted treatment reduces relapse in children with AML

By

Combining the monoclonal antibody gemtuzumab with standard chemotherapy significantly reduced the risk of relapse and increased rates of disease-free survival in pediatric patients with AML. Posttreatment relapse rates are a major indicator of potential for long-term survival in children with the disease.

Drug-antibody pair has promising activity in non-Hodgkin lymphoma

By

A toxin linked to a targeted monoclonal antibody has shown compelling antitumor activity in patients with non-Hodgkin lymphomas (NHLs) who were no longer responding to treatment, according to a new report.

Stem cells offer new therapeutic path for colon cancer

By

A promising new approach to treating colorectal cancer involves disarming the gene that drives self-renewal in the stem cells that are the root cause of disease, treatment resistance, and relapse. Colorectal cancer is the third leading cause of cancer-related death in the Western world.

Potential new treatments for acute myeloid leukemia

By

In separate studies on CEBPA mutations in AML subtypes, researchers successfully identified a gene known as Sox4 as a potential therapeutic target along with a class of anticancer drugs—histone deacetylase (HDAC) inhibitors—as potential candidates in the treatment of AML subtypes.

Targeting cancer to improve drug delivery

By

Selectively targeting only cancer cells could help to avoid healthy cells and side effects from treatments.

Tumor genetics customize treatments for deadly prostate cancer

By

A new study is using genomic sequencing to develop customized treatments for men with castration-resistant prostate cancer.

Two targeted drugs with chemo safe and effective in advanced NSCLC

By

A phase II study is the first to show that adding two targeted therapy drugs to the standard chemotherapy regimen is safe and effective as first-line treatment of advanced non-small cell lung cancer.

Drug-resistant melanoma and breast cancer treated with potential new drug

By

A small-molecule inhibitor of CDK 4/6 being developed showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies.

Targeted radiotherapy safe and effective for elderly with pancreatic cancer

By

A highly targeted cancer radiation therapy may offer a safe and effective treatment option for elderly patients with pancreatic cancer who are unable to undergo surgery or combined chemotherapy and radiation therapy.

Immune system harnessed to fight pancreatic cancer

By

Substantial tumor regressions among some patients with advanced pancreatic cancer occurred in a recent clinical trial that paired the standard chemotherapy for pancreatic cancer, gemcitabine, with an agonist CD40 antibody.

First randomized trial of targeted cancer medicine in all tumor types

By

The SHIVA trial is the first randomized trial to look at patient outcomes after treatments were chosen based on individual molecular profiles of each person's tumor.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs